Pharmacodynamic Substances and Mechanisms of Da Chengqitang in Treating Stroke： A Review
10.13422/j.cnki.syfjx.20241914
- VernacularTitle:大承气汤在脑卒中治疗中的药效物质与作用机制研究进展
- Author:
Yizhi YAN
1
;
Xinyi LIU
1
;
Yang DUAN
1
;
Miaoqing LONG
1
;
Chaoya LI
2
;
Qiang LI
1
;
Yi'an CHEN
1
;
Shasha YANG
1
;
Yue ZHANG
1
;
Peng ZENG
1
Author Information
1. School of Basic Medical Sciences， Hengyang Medical School， University of South China， Hengyang 421001， China
2. Chenzhou No.1 People's Hospital， Chenzhou 423000， China
- Publication Type:Journal Article
- Keywords:
Da Chengqitang;
stroke;
pharmacodynamic basis;
quality marker（Q-marker）;
mechanism
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(9):297-306
- CountryChina
- Language:Chinese
-
Abstract:
Stroke is the main cause of death and disability among adults in China and is characterized by high incidence， disability， mortality， and recurrence rates. The combination of traditional Chinese and Western medicine has great potential in treating stroke and its sequelae. The classic traditional Chinese medicine prescription Da Chengqitang （DCQT） has a long history and proven efficacy in treating stroke. Clinically， DCQT is often used to treat stroke and its sequelae. However， the number and quality of clinical trials of DCQT in treating stroke need to be improved. Because of the insufficient basic research， the active ingredients and multi-target mechanism of action of DCQT remain unclear. Our research group has previously confirmed that DCQT can effectively reverse neurological damage， reduce iron deposition， and downregulate the levels of pro-inflammatory cytokines in the rat model of hemorrhagic stroke. The treatment mechanism is related to the nuclear factor erythroid 2-related factor 2 （Nrf2）-mediated signaling pathway and p38 mitogen-activated protein kinase （MAPK） signaling-mediated microglia activation. To clarify the pharmacodynamic basis and anti-stroke mechanism of DCQT， this article reviews the research progress in the treatment of stroke with DCQT in terms of clinical trials， pharmacodynamic material basis， safety evaluation， and mechanisms of absorbed components. This article summarizes 45 major phytochemical components of DCQT， 11 of which are currently confirmed absorbed components. Among them， emodin， rhein， chrysophanol， aloe-emodin， synephrine， hesperidin， naringin， magnolol， and honokiol can be used as quality markers （Q-markers） of DCQT. The mechanism of DCQT in treating stroke is complex， involving regulation of inflammatory responses， neuronal damage， oxidative stress， blood-brain barrier， brain-derived neurotrophic factor， and anti-platelet aggregation. This article helps to deeply understand the pharmacodynamic basis and mechanism of DCQT in treating stroke and provides a theoretical basis for the clinical application of DCQT in treating stroke and the development of stroke drugs.
